Delivering the vision of a world where disease is no longer an insurmountable burden for patients and healthcare professionals would be a phenomenal achievement in the history of medicine.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh